Patents Examined by Nelson C Blakely, III
-
Patent number: 8227514Abstract: Travoprost medicament compositions for non-daily topical application are useful for simulating or inducing the growth and/or decreasing the loss and/or increasing the density and/or reducing the heterogeneity in the diameter of human hair shafts/follicles, e.g., for the treatment of androgenic alopecia, such medicament compositions being at least twice applied over a time interval of greater than 24 hours.Type: GrantFiled: February 23, 2010Date of Patent: July 24, 2012Assignee: Galderma Research & DevelopmentInventors: Sandrine Rethore, Carine Rosignoli, André Jomard, Johannes Voegel
-
Patent number: 8202886Abstract: A small molecular inhibitor of E2F (HLM006474) was identified using a computer-based virtual screen and the known crystal structure of the DNA bound E2F4/DP2 heterodimer. Treatment of multiple cell lines resulted in the loss of intracellular E2F4 DNA-binding activity. Overnight exposure to HLM006474 resulted in down regulation of total E2F4 protein as well as several known E2F targets. The effects of treatment on different cell lines included a reduction in cell proliferation and an increase in apoptosis. Apoptosis was induced in a manner distinct from cisplatin and doxorubicin. E2F4-null MEFs (mouse embryo fibroblasts) were less sensitive than wildtype counterparts to the apoptosis-inducing activity of the compound revealing its biological specificity. A375 cells were extremely sensitive to the apoptosis-inducing activity of the compound in two-dimensional culture and HLM006474 was a potent inhibitor of melanocytes proliferation and subsequent invasion in a three-dimensional tissue culture model system.Type: GrantFiled: August 31, 2010Date of Patent: June 19, 2012Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South FloridaInventors: Douglas W. Cress, Yihong Ma
-
Patent number: 8183206Abstract: It is intended to provide drugs for treating ischemic diseases which are safe and have little side effects. Namely, drugs having a combination of an antithrombotic agent and a pyrazolone derivative defined in the description or its pharmaceutically acceptable salt.Type: GrantFiled: September 13, 2002Date of Patent: May 22, 2012Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Katsumi Kurita, Tadashi Tanaka, Masahiko Tanaka, Jyunichi Eguchi, Satoshi Yuki, Narihiko Yoshii
-
Patent number: 8030318Abstract: Substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.Type: GrantFiled: March 27, 2006Date of Patent: October 4, 2011Assignee: Tibotec Pharmaceuticals Ltd.Inventors: Kenneth Alan Simmen, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson, Sarvajit Chakravarty, Barry Patrick Hart
-
Patent number: 8026251Abstract: The present invention relates to a method for treating or alleviating migraines, by administering to a patient in need thereof compound (I), or salts thereof, or pharmaceutical preparations thereof comprising mixtures of compound (I) or salts thereof with pharmaceutically-acceptable diluents wherein: R represents —NHC(O)OR3; and R3 represents methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or phenylmethyl.Type: GrantFiled: January 26, 2008Date of Patent: September 27, 2011Inventor: Hesheng Zhang
-
Patent number: 7959962Abstract: The invention relates to long-chain inulin and its preparation from artichoke roots, its use in foodstuffs and cosmetic preparations and foodstuffs and cosmetic preparations having the long-chain inulin.Type: GrantFiled: April 12, 2006Date of Patent: June 14, 2011Assignee: Bayer CropScience AGInventors: Elke Hellwege, Roger Peeters, Jens Pilling
-
Patent number: 7935717Abstract: The invention is directed to a method for treating hypertriglyceridemia, dyslipidemia and hypercholesterolemia by administration of a 1-methylnicotinamide salt.Type: GrantFiled: January 7, 2005Date of Patent: May 3, 2011Assignee: Pharmena Spolka Akcyjna (Pharmena S.A.)Inventors: Jerzy Gebicki, Stefan Chlopicki
-
Patent number: 7910617Abstract: A method for suppressing the number of peripheral blood lymphocytes involving administering to a human in need thereof a pharmaceutically effective amount of a compound which is (2R) -2-amino-2-methyl-4-{1-methyl-5-[4-(4-methylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol or a pharmacologically acceptable salt thereof, such as the hydrochloride salt.Type: GrantFiled: February 23, 2005Date of Patent: March 22, 2011Assignee: Sankyo Company, LimitedInventors: Takahide Nishi, Toshiyasu Takemoto, Shojiro Miyazaki, Takaichi Shimozato, Futoshi Nara, Takashi Izumi
-
Patent number: 7902254Abstract: Disclosed is a method for treating PPAR (peroxisome proliferator activated receptor)-mediated diseases, such as diabetes mellitus, which includes administering to a subject an effective amount of macelignan represented by the following Formula (I): or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 27, 2006Date of Patent: March 8, 2011Assignee: Newtree Co., Ltd.Inventors: Jae-Kwan Hwang, Kyu-Lee Han, Jong-Hee Sohn, Ah-Jin Kim, Jeong-Han Choo, Jae-Young Lee, Jeong-Hwan Kim, Do Un Kim, Heechul Chung, Jae Youn Chung
-
Patent number: 7875641Abstract: The present invention relates to sesquihydrate hydrochloride salt of irbesartan and pharmaceutical compositions comprising the same.Type: GrantFiled: July 29, 2005Date of Patent: January 25, 2011Assignee: KRKA Tovarna Zdravil, D.D., Novo MestoInventors: Silvo Zupancic, Matej Smrkolj, Renata Jaske
-
Patent number: 7872049Abstract: A pharmaceutical preparation containing the active substance glyceryl trinitrate having improved storage stability in a container. The improved storage stability is achieved by the addition of a proton-absorbing substance either as part of the preparation as placed into the container or applied to the surface of the preparation's storage container before the remaining components of the preparation are placed into the container. The preparation can preferably be filled into a plastic bottle having a spray pump.Type: GrantFiled: May 27, 2010Date of Patent: January 18, 2011Assignee: G. Pohl-Boskamp GmbH & Co. KGInventors: Rolf Grotelüschen, Henning Ueck, Thomas Zimmeck
-
Patent number: 7842714Abstract: The present invention provides an aqueous ophthalmic solution having an effective amount of ketorolac which includes carboxymethyl cellulose in an aqueous solution wherein the concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.Type: GrantFiled: March 2, 2009Date of Patent: November 30, 2010Assignee: Allergan, Inc.Inventors: Eldon Q. Farnes, Mayssa Attar, Rhett M. Schiffman, Chin-Ming Chang, Richard S. Graham, Devin F. Welty
-
Patent number: 7632850Abstract: The present invention provides a compound of the formula (I): in which R1, R2, R3, A and n are described and set forth more fully herein. Also provided are their preparation and their application in therapy.Type: GrantFiled: July 21, 2005Date of Patent: December 15, 2009Assignee: Sanofi-aventisInventors: Ahmed Abouabdellah, Antonio Almario Garcia, Christian Hoornaert, Antoine Ravet